Cargando…
Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report
INTRODUCTION: Miller-Fisher Syndrome (MFS) is a variant of Guillain–Barré syndrome (GBS), an acute immune-mediated neuropathy, which manifests as a rapidly evolving areflex motor paralysis. This syndrome presents as a classic triad: ophthalmoplegia, areflexia, and ataxia. MFS is usually benign and s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667853/ https://www.ncbi.nlm.nih.gov/pubmed/36384584 http://dx.doi.org/10.1186/s13256-022-03592-4 |
_version_ | 1784831794384732160 |
---|---|
author | Pirola, Fernanda Junqueira Cesar Santos, Bruno Antônio Müzel Sapienza, Gabriela Feres Cetrangolo, Lucas Yuri Geranutti, Caio Henrique Wthen Gambacorta de Aguiar, Paulo Henrique Pires |
author_facet | Pirola, Fernanda Junqueira Cesar Santos, Bruno Antônio Müzel Sapienza, Gabriela Feres Cetrangolo, Lucas Yuri Geranutti, Caio Henrique Wthen Gambacorta de Aguiar, Paulo Henrique Pires |
author_sort | Pirola, Fernanda Junqueira Cesar |
collection | PubMed |
description | INTRODUCTION: Miller-Fisher Syndrome (MFS) is a variant of Guillain–Barré syndrome (GBS), an acute immune-mediated neuropathy, which manifests as a rapidly evolving areflex motor paralysis. This syndrome presents as a classic triad: ophthalmoplegia, areflexia, and ataxia. MFS is usually benign and self-limited. CASE REPORT: A Caucasian patient was admitted to our hospital with the flu, loss of bilateral strength in the lower limbs and upper limbs and sudden-onset ataxia 7 days after receiving a first dose of the Oxford/AstraZeneca COVID-19 vaccine. On neurological examination, the patient had Glasgow Coma Scale score of 15, with absence of meningeal signs; negative Babinski sign; grade 2 strength in the lower limbs and grade 4 strength in the upper limbs; axial and appendicular cerebellar ataxia; and peripheral facial diparesis predominantly on the right, without conjugate gaze deviation. Cerebrospinal fluid (CSF) was collected on admission, and analysis revealed albuminocytological dissociation with CSF protein of 148.9 mg/dL; leukocytes, 1; chlorine, 122; glucose, 65 mg/mL; red cells, 2; and non-reactive venereal disease research laboratory test result. The COVID-19 IgG/IgM rapid immunological test was negative. Electroneuromyography revealed a recent moderate-grade and primarily sensory and motor demyelinating polyneuropathy with associated proximal motor block. DISCUSSION AND CONCLUSION: Miller-Fisher Syndrome may be related to events other than infections prior to neuropathy, as in the case reported here. The patient presented strong correlations with findings for MFS reported in the literature, such as the clinical condition, the results of electroneuromyography, and results of the CSF analysis typical for MFS. When treatment was provided as proposed in the literature, the disease evolved with improvement. Ultimately, the diagnosis of incomplete MFS was made, including acute ataxic neuropathy (without ophthalmoplegia). |
format | Online Article Text |
id | pubmed-9667853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96678532022-11-16 Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report Pirola, Fernanda Junqueira Cesar Santos, Bruno Antônio Müzel Sapienza, Gabriela Feres Cetrangolo, Lucas Yuri Geranutti, Caio Henrique Wthen Gambacorta de Aguiar, Paulo Henrique Pires J Med Case Rep Case Report INTRODUCTION: Miller-Fisher Syndrome (MFS) is a variant of Guillain–Barré syndrome (GBS), an acute immune-mediated neuropathy, which manifests as a rapidly evolving areflex motor paralysis. This syndrome presents as a classic triad: ophthalmoplegia, areflexia, and ataxia. MFS is usually benign and self-limited. CASE REPORT: A Caucasian patient was admitted to our hospital with the flu, loss of bilateral strength in the lower limbs and upper limbs and sudden-onset ataxia 7 days after receiving a first dose of the Oxford/AstraZeneca COVID-19 vaccine. On neurological examination, the patient had Glasgow Coma Scale score of 15, with absence of meningeal signs; negative Babinski sign; grade 2 strength in the lower limbs and grade 4 strength in the upper limbs; axial and appendicular cerebellar ataxia; and peripheral facial diparesis predominantly on the right, without conjugate gaze deviation. Cerebrospinal fluid (CSF) was collected on admission, and analysis revealed albuminocytological dissociation with CSF protein of 148.9 mg/dL; leukocytes, 1; chlorine, 122; glucose, 65 mg/mL; red cells, 2; and non-reactive venereal disease research laboratory test result. The COVID-19 IgG/IgM rapid immunological test was negative. Electroneuromyography revealed a recent moderate-grade and primarily sensory and motor demyelinating polyneuropathy with associated proximal motor block. DISCUSSION AND CONCLUSION: Miller-Fisher Syndrome may be related to events other than infections prior to neuropathy, as in the case reported here. The patient presented strong correlations with findings for MFS reported in the literature, such as the clinical condition, the results of electroneuromyography, and results of the CSF analysis typical for MFS. When treatment was provided as proposed in the literature, the disease evolved with improvement. Ultimately, the diagnosis of incomplete MFS was made, including acute ataxic neuropathy (without ophthalmoplegia). BioMed Central 2022-11-16 /pmc/articles/PMC9667853/ /pubmed/36384584 http://dx.doi.org/10.1186/s13256-022-03592-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Pirola, Fernanda Junqueira Cesar Santos, Bruno Antônio Müzel Sapienza, Gabriela Feres Cetrangolo, Lucas Yuri Geranutti, Caio Henrique Wthen Gambacorta de Aguiar, Paulo Henrique Pires Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title | Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title_full | Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title_fullStr | Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title_full_unstemmed | Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title_short | Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report |
title_sort | miller–fisher syndrome after first dose of oxford/astrazeneca coronavirus disease 2019 vaccine: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667853/ https://www.ncbi.nlm.nih.gov/pubmed/36384584 http://dx.doi.org/10.1186/s13256-022-03592-4 |
work_keys_str_mv | AT pirolafernandajunqueiracesar millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport AT santosbrunoantoniomuzel millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport AT sapienzagabrielaferes millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport AT cetrangololucasyuri millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport AT geranutticaiohenriquewthengambacorta millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport AT deaguiarpaulohenriquepires millerfishersyndromeafterfirstdoseofoxfordastrazenecacoronavirusdisease2019vaccineacasereport |